News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Receives Fee Waivers from FDA
Napo Pharmaceuticals and Jaguar Health receive waivers from FDA for Mytesi and Canalevia fees for 2027. Jaguar develops GI drugs from plants; focus on rare disorders and mental health. For safety information, visit Mytesi.com and Canalevia.com -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Napo Pharmaceuticals enters extension phase with blinded doses of crofelemer to support NDA filing for ultrarare pediatric disease MVID in mid-2027 -
